Autologous Tumor Cell Vaccine
Refractory Plasma Cell Neoplasm
National Cancer Institute (NCI)vaccinePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Refractory Plasma Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Keyhole Limpet Hemocyanin National Cancer Institute (NCI) | Phase 2 | B |
Sargramostim National Cancer Institute (NCI) | Phase 2 | B |
Evomela National Cancer Institute (NCI) | Phase 2 | B |
Arsenic Trioxide | Phase 2 | CCC |
Thalidomide | Phase 2 | CCC |
DEXAMETHASONE | Phase 2 | CCC |
Same molecule, other indications
Autologous Tumor Cell Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →